In the next segment, Dr. Alder presents the case of a patient with ALK-positive metastatic non-small cell lung cancer and discusses first-line targeted therapy, management of its adverse effects, and repeat testing at progression.

All right, so I'm gonna walk you through a diagnosis and management of ALK positive non-small cell lung cancer.

So you can see in that little graph there, ALK fusions account for about 4% of non-small cell lung cancer.

Fairly small slice, but it's a really important one.

This has been really nicely went over.

We have some great treatments in this ALK positive group.

And so always super important to test.

So this is also something that is now